Pharmedic Pharmaceutical Medicinal JSC (HNX:PMC)

HNX:PMC Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jan 1, 2021
Revenue	521,502	498,185	485,186	472,274	414,232	460,764
Revenue Growth (YoY)	5.70%	2.68%	2.73%	14.01%	-10.10%	-0.86%
Cost of Revenue	304,596	310,972	315,134	285,918	266,740	284,276
Gross Profit	216,906	187,213	170,053	186,356	147,492	176,488
Selling, General & Admin	118,960	96,729	85,645	95,588	74,912	90,801
Operating Expenses	119,601	96,729	85,645	95,588	74,912	90,801
Operating Income	97,305	90,484	84,408	90,768	72,580	85,687
Interest Expense	-259.73	-	-	-	-	-
Interest & Investment Income	7,687	9,557	19,853	13,178	9,363	7,803
Currency Exchange Gain (Loss)	2.37	2.37	17.19	-43.02	27.29	-104.1
Other Non Operating Income (Expenses)	-47.48	269.41	148.96	-675.76	-1,022	55.09
EBT Excluding Unusual Items	104,687	100,313	104,427	103,227	80,949	93,441
Gain (Loss) on Sale of Assets	664.55	-	175.45	1,253	334.97	259.09
Pretax Income	105,352	100,313	104,602	104,480	81,284	93,700
Income Tax Expense	21,141	20,180	21,038	21,064	16,524	19,082
Net Income	84,211	80,133	83,564	83,416	64,760	74,618
Preferred Dividends & Other Adjustments	21,636	21,636	22,562	22,522	17,485	20,147
Net Income to Common	62,575	58,497	61,002	60,894	47,275	54,471
Net Income Growth	-1.01%	-4.11%	0.18%	28.81%	-13.21%	0.27%
Shares Outstanding (Basic)	9	9	9	9	9	9
Shares Outstanding (Diluted)	9	9	9	9	9	9
EPS (Basic)	6705.00	6268.07	6536.47	6524.89	5065.55	5836.69
EPS (Diluted)	6704.93	6268.00	6536.00	6524.89	5065.55	5836.69
EPS Growth	0.11%	-4.10%	0.17%	28.81%	-13.21%	0.27%
Free Cash Flow	-60,448	39,227	86,678	31,675	58,885	71,003
Free Cash Flow Per Share	-6477.09	4203.23	9287.65	3394.02	6309.63	7608.06
Dividend Per Share	1400.000	2400.000	19100.000	3000.000	2400.000	-
Dividend Growth	-78.46%	-87.44%	536.67%	25.00%	-	-
Gross Margin	41.59%	37.58%	35.05%	39.46%	35.61%	38.30%
Operating Margin	18.66%	18.16%	17.40%	19.22%	17.52%	18.60%
Profit Margin	12.00%	11.74%	12.57%	12.89%	11.41%	11.82%
Free Cash Flow Margin	-11.59%	7.87%	17.87%	6.71%	14.21%	15.41%
EBITDA	108,034	101,755	96,345	103,311	86,549	100,040
EBITDA Margin	20.72%	20.42%	19.86%	21.88%	20.89%	21.71%
D&A For EBITDA	10,729	11,271	11,938	12,543	13,968	14,353
EBIT	97,305	90,484	84,408	90,768	72,580	85,687
EBIT Margin	18.66%	18.16%	17.40%	19.22%	17.52%	18.60%
Effective Tax Rate	20.07%	20.12%	20.11%	20.16%	20.33%	20.36%
Revenue as Reported	521,502	498,185	485,186	472,274	414,232	460,764

Source: S&P Global Market Intelligence. Standard template. Financial Sources.